Alexion Pharmaceuticals (ALXN) PT Lowered to $186 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release
June 7, 2016 9:46 AM EDTOppenheimer maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $221.00 (from $228.00), following the company's announced top-line data from Phase 3 REGAIN study of eculizumab (Soliris) in refractory generalized myasthenia gravis (rGMG).
Analyst Christopher Marai commented, "Alexion announced... More
Alexion (ALXN) Buy On Weakness - Piper Jaffray
June 7, 2016 9:29 AM EDTPiper Jaffray analyst, Joshua Schimmer, noted that after the close, Alexion Pharmaceuticals (NASDAQ: ALXN) reported topline results from Phase 3 REGAIN study of Soliris for the treatment of refractory generalized myasthenia gravis. While the study failed to meet the primary efficacy endpoint of change from baseline... More
Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
June 7, 2016 6:18 AM EDTBMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing data from the Phase III trial of Soliris in Myasthenia Gravis (MG). Although the totality of the data suggests significant benefit, the study missed its primary endpoint... More
Alexion Pharma (ALXN) Phase 3 REGAIN Study of Eculizumab Did Not Reach Statistical Significance
June 6, 2016 4:03 PM EDTAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis (gMG). Refractory gMG is an ultra-rare segment of MG - a debilitating, complement-mediated neuromuscular disease - in which... More
